Incyte Corp GVHD Update Call: Approval in cGVHD and Syndax Collaboration Transcript
Greetings, ladies and gentlemen, and welcome to the Incyte's GVHD update conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ms. Christine Chiou, Head of Investor Relations. Thank you. Please go ahead.
Thank you, Donna. Good morning, and welcome to Incyte's conference call and webcast to discuss the recent approval of Jakafi in chronic GVHD and this morning's announcement of our collaboration with Syndax Pharmaceuticals.
Speaking on the call today are Herve and Peter Langmuir, our Group Vice President of Development in Oncology Targeted Therapeutics. Barry and Christiana will also participate in the Q&A session.
Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements and are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our 10-Q for the quarter ended
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |